Published in Narrat Inq Bioeth on January 01, 2012
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Tuberculosis. N Engl J Med (2013) 4.75
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS (2008) 2.35
Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis (2011) 2.07
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96
Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS (2003) 1.88
Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis (2011) 1.83
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol (2002) 1.74
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Gut microbial colonisation in premature neonates predicts neonatal sepsis. Arch Dis Child Fetal Neonatal Ed (2012) 1.59
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics (2007) 1.38
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr (2003) 1.29
Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr (2006) 1.27
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J (2009) 1.20
Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology (2009) 1.20
Disrespect and abuse during childbirth in Tanzania: are women living with HIV more vulnerable? J Acquir Immune Defic Syndr (2014) 1.18
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health (2008) 1.14
The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis (2011) 1.07
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol (2008) 1.02
Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol (2003) 1.00
Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis (2003) 1.00
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression. AIDS (2004) 0.97
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis (2002) 0.96
Community health workers to improve antenatal care and PMTCT uptake in Dar es Salaam, Tanzania: a quantitative performance evaluation. J Acquir Immune Defic Syndr (2014) 0.94
Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes. Soc Sci Med (2009) 0.93
Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics (2008) 0.92
Optimal treatment of Codisease due to HIV and tuberculosis. J Infect Dis (2011) 0.92
Utility of dual skin tests to evaluate tuberculin skin test reactions of 10 to 14 mm in healthcare workers. Infect Control Hosp Epidemiol (2003) 0.90
Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol (2011) 0.90
Tuberculosis vaccines: time to reset the paradigm? Thorax (2013) 0.90
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J (2014) 0.88
CD4/CD8 T-cell ratio predicts HIV infection in infants: the National Heart, Lung, and Blood Institute P2C2 Study. J Allergy Clin Immunol (2007) 0.88
Increased mortality in rural patients with HIV in New England. AIDS Res Hum Retroviruses (2007) 0.88
Molecular epidemiology of HIV-associated tuberculosis in Dar es Salaam, Tanzania: strain predominance, clustering, and polyclonal disease. J Clin Microbiol (2012) 0.88
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis (2009) 0.87
DOTS implementation in a post-war, United Nations-administered territory: lessons from Kosovo. Respir Med (2007) 0.86
Recent trends in infective endocarditis: influence of case definitions. Curr Opin Cardiol (2004) 0.86
Specificity of the tuberculin skin test and the T-SPOT.TB assay among students in a low-tuberculosis incidence setting. J Am Coll Health (2012) 0.86
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J Allergy Clin Immunol (2007) 0.85
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis (2012) 0.84
Auditory impairments in HIV-infected individuals in Tanzania. Ear Hear (2014) 0.84
Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2006) 0.84
Challenges to re-enrolling perinatally HIV-infected and HIV-exposed but uninfected children into a prospective cohort study: strategies for locating and recruiting hard-to-reach families. Paediatr Perinat Epidemiol (2006) 0.83
Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine (2004) 0.83
Health department costs of managing persons with suspected and noncounted tuberculosis in New York City, Three Texas counties, and Massachusetts. J Public Health Manag Pract (2006) 0.82
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). J Allergy Clin Immunol (2006) 0.82
Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J (2004) 0.82
Association of pol diversity with antiretroviral treatment outcomes among HIV-infected African children. PLoS One (2013) 0.81
Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania. Tuberculosis (Edinb) (2013) 0.81
Children's medicines in Tanzania: a national survey of administration practices and preferences. PLoS One (2013) 0.81
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis (2006) 0.81
The time to treat the children is now. J Infect Dis (2007) 0.80
Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2002) 0.80
Routine childhood bacille Calmette Guérin immunization and HIV infection. Clin Infect Dis (2006) 0.80
Dual skin tests with Mycobacterium avium sensitin and PPD to detect misdiagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis (2011) 0.80
GB virus C infection in children with perinatal human immunodeficiency virus infection. Pediatr Infect Dis J (2005) 0.79
Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J (2002) 0.79
Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther (2003) 0.79
Tuberculosis vaccine trials. Lancet Infect Dis (2005) 0.79
Proposed definitions for epidemiologic and clinical studies of Mycobacterium avium complex pulmonary disease. PLoS One (2013) 0.78
Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J (2004) 0.77
Deficiencies of macronutrient intake among HIV-positive breastfeeding women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr (2014) 0.76
Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis. J Infect Dis (2013) 0.76
Auditory Impairments in HIV-Infected Children. Ear Hear (2016) 0.75
Invalid screening algorithm. Int J Tuberc Lung Dis (2009) 0.75
Diagnosis and treatment of tuberculosis among children at an HIV care program in Dar es Salaam, Tanzania. Pediatr Infect Dis J (2014) 0.75
The importance of culture for diagnosing tuberculosis. Clin Infect Dis (2005) 0.75
BCG vaccination in children. BMJ (2008) 0.75
Interferon assay compared to tuberculin skin testing for latent tuberculosis detection. JAMA (2002) 0.75
Maintenance of Sensitivity of the T-SPOT.TB Assay after Overnight Storage of Blood Samples, Dar es Salaam, Tanzania. Tuberc Res Treat (2012) 0.75
Dual skin testing for latent tuberculosis infection: a decision analysis. Am J Prev Med (2003) 0.75
Current administration practices and preferred formulations of children's medicines in Tanzania: summary of survey findings. Int J Pharm (2012) 0.75
HIV-1 resistance to antiretroviral agents: relevance to mothers and infants in the breastfeeding setting. Adv Exp Med Biol (2012) 0.75
Diagnosis of HIV: challenges and strategies for HIV prevention and detection among pregnant women and their infants. Clin Perinatol (2010) 0.75
Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1. AIDS (2017) 0.75